Amongst all 19 human UGT enzymes, UGT2B17 largely predominates in human leukemic B-cells, although with significant variability (CVUGT2B17 = 242.9%; n = 291 CLL patients) (Figure 5B). Here, UGT2B17 is linked to B-cell chronic lymphocytic leukemia.